In this study, we describe new mouse models, based on Brca1-def and Bard1-def orthotopic allografts, that recapitulate the clinical response and progression phases of PARPi therapy observed in BRCA1/2-mutant breast cancer patients. The gene discussed is BARD1; the disease is breast cancer.